Clinical Trial Update: Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 safety study of the investigational hepatitis C drug HCV-796 in subjects with hepatic insufficiency and in healthy adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Liver Failure

Drugs mentioned

• HCV-796

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hepatitis C, Hepatic Insufficiency | Phase 1 | Status: COMPLETED